{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:37:17Z","timestamp":1780720637740,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) are recommended to receive double antithrombotic therapy including an antiplatelet agent and direct oral anticoagulants (DOAC). The efficacy and safety of aspirin vs. clopidogrel as a combination therapy with DOAC were compared in the present study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Patient data from the Korea National Health Insurance Service from 2013 to 2020 were analysed. A total of 9157 patients with AF who received double antithrombotic therapy consisting of an antiplatelet agent and a DOAC after PCI were included. Patients were classified into the clopidogrel or aspirin group and 1:1 propensity score (PS) matching was performed. The major adverse cardiovascular event (MACE) was defined as a composite of cardiovascular death, myocardial infarction, ischaemic stroke, or systemic thromboembolism. After PS matching, the clopidogrel and aspirin groups consisted of 2882 patients each. During a median follow-up of 20.1 months, the incidence of MACE was not significantly different between the two groups (hazard ratio [HR] for clopidogrel group 0.91, 95% confidence interval [CI] 0.81\u20131.02). The incidence of ischaemic endpoints did not significantly differ between the two groups. A significant difference was not observed in the incidence of major bleeding events (HR 0.94, 95% CI 0.78\u20131.12) and net adverse clinical events (HR 0.93, 95% CI 0.84\u20131.03).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with AF receiving double antithrombotic therapy after PCI, aspirin and clopidogrel showed similar efficacy and safety when used in combination with DOAC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf043","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:48:10Z","timestamp":1748418490000},"page":"532-539","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes with the use of aspirin vs. clopidogrel as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4626-3089","authenticated-orcid":false,"given":"Soohyun","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Incheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , 56 Dongsuro, Bupyeonggu, Incheon 21431 ,","place":["Republic of Korea"]},{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1560-5670","authenticated-orcid":false,"given":"Soyoon","family":"Park","sequence":"additional","affiliation":[{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]},{"name":"Division of Cardiology, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-8689","authenticated-orcid":false,"given":"Hwajung","family":"Kim","sequence":"additional","affiliation":[{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]},{"name":"Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , 62 Yeouidodong, Yeongdeungpogu, Seoul 07345 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilar","family":"Aung","sequence":"additional","affiliation":[{"name":"Cardiac Medical Unit, No. 2 Defense Service General Hospital , Thaikchaung, Nay Pyi Taw 08011 ,","place":["Myanmar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6805-0416","authenticated-orcid":false,"given":"Sung-Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]},{"name":"Division of Cardiology, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyuk","family":"Chang","sequence":"additional","affiliation":[{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]},{"name":"Division of Cardiology, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-1943","authenticated-orcid":false,"given":"Young","family":"Choi","sequence":"additional","affiliation":[{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]},{"name":"Division of Cardiology, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , 222 Banpodaero, Seochogu, Seoul 06591 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2025092123021041500_pvaf043-B1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025092123021041500_pvaf043-B2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res"},{"key":"2025092123021041500_pvaf043-B3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092123021041500_pvaf043-B4","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"2025092123021041500_pvaf043-B5","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.3390\/jcm12237487","article-title":"Effectiveness of early direct oral anticoagulant monotherapy within one year of coronary stent implantation in patients with atrial fibrillation: a nationwide population-based study","volume":"12","author":"Hwang","year":"2023","journal-title":"J Clin Med"},{"key":"2025092123021041500_pvaf043-B6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2020-318750","article-title":"Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation","volume":"108","author":"Choi","year":"2022","journal-title":"Heart"},{"key":"2025092123021041500_pvaf043-B7","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025092123021041500_pvaf043-B8","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025092123021041500_pvaf043-B9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092123021041500_pvaf043-B10","first-page":"485","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"378","author":"Baduashvili","year":"2018","journal-title":"N Engl J Med"},{"key":"2025092123021041500_pvaf043-B11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2025092123021041500_pvaf043-B12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/FJC.0000000000000973","article-title":"Real-world experience with antiplatelet agents after percutaneous coronary intervention in patients with an indication for an oral anticoagulant","volume":"77","author":"Tanner","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025092123021041500_pvaf043-B13","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2025092123021041500_pvaf043-B14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after Complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025092123021041500_pvaf043-B15","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3346\/jkms.2024.39.e191","article-title":"Optimal antithrombotic therapy beyond 1-year after coronary revascularization in patients with atrial fibrillation","volume":"39","author":"Kim","year":"2024","journal-title":"J Korean Med Sci"},{"key":"2025092123021041500_pvaf043-B16","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"Eurointervention"},{"key":"2025092123021041500_pvaf043-B17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2025092123021041500_pvaf043-B18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2025092123021041500_pvaf043-B19","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"2025092123021041500_pvaf043-B20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"2025092123021041500_pvaf043-B21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025092123021041500_pvaf043-B22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"2025092123021041500_pvaf043-B23","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.jcin.2022.08.009","article-title":"P2Y12 inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: a network meta-analysis","volume":"15","author":"Ando","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123021041500_pvaf043-B24","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1093\/eurheartj\/ehae617","article-title":"Aspirin versus clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial","volume":"45","author":"Watanabe","year":"2024","journal-title":"Eur Heart J"},{"key":"2025092123021041500_pvaf043-B25","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41598-020-58665-5","article-title":"Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"2025092123021041500_pvaf043-B26","doi-asserted-by":"crossref","first-page":"e4672","DOI":"10.1097\/MD.0000000000004672","article-title":"Suboptimal use of non-vitamin K antagonist oral anticoagulants: results from the RAMSES study","volume":"95","author":"Basaran","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025092123021041500_pvaf043-B27","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2025092123021041500_pvaf043-B28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1253\/circrep.CR-20-0026","article-title":"Impact of direct oral anticoagulant off-label reduced dose in combination with antiplatelet agents on clinical outcome- propensity score-matching analysis from the DIRECT real-world non-valvular atrial fibrillation registry","volume":"2","author":"Kobayashi","year":"2020","journal-title":"Circ Rep"},{"key":"2025092123021041500_pvaf043-B29","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"2025092123021041500_pvaf043-B30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cgh.2023.12.022","article-title":"Reduction of upper gastrointestinal bleeding risk with proton pump inhibitor therapy in Asian patients with atrial fibrillation receiving direct oral anticoagulant: a nationwide population-based cohort study","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025092123021041500_pvaf043-B31","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf043\/63397350\/pvaf043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/6\/532\/63397350\/pvaf043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/6\/532\/63397350\/pvaf043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T03:02:30Z","timestamp":1758510150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/6\/532\/8152689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf043","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,29]]}}}